Table 3.

Model adverse event^a,^b rates by treatment

Parameter	Estimatea	Reference
CNS symptomsc
Atripla®	1.8%	2
Stribild™	0.6%	2
Renal abnormalities
Atripla	0%	2
Stribild
No AKI	0.22%	2
AKI	0.14%	2
CKD with dialysisd	0.03%	Expert opinion
Rashc
First-line
Atripla	1.4%	2
Stribild	0%	2
Second-line	0.7%	22
Third-line	1.8%	22,25,28
Elevated lipids
First-line
Atripla	1.3%	29
Stribild	1.0%	29
Second-line	1.4%	26,27
Third-line	2.7%	25,26,30,31
Other eventsc
First-line
Atripla	0.5%	2
Stribild	0.5%	2
Second-line	0.4%	22
Third-line	0.7%	22,28

Notes:

^aValues are reported as probability per 12-week model cycle and are rounded;

^bdefined as events causing treatment discontinuation except for elevated lipids causing initiation of lipid-lowering therapy, for which treatment continues with an additional cost;

^cevents occur only during the first cycle of each line of therapy;

^dpatients with AKI may progress to CKD with dialysis only during the cycle following the acute AKI event.

Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; CNS, central nervous system.